Company news

NexGel, Inc news in 2026

NexGel, Inc's news releases, calls and decks from 2026, newest first.

View company

NEXGEL Regains Compliance with Nasdaq Listing Requirement

October 27, 2026

NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness

October 12, 2026

NEXGEL Announces Dial-In Details for Investor Update Call

September 23, 2026

NEXGEL Announces Date for Investor Update Call

September 16, 2026

NEXGEL announces leadership transition and strategic review initiative

August 20, 2026

NEXGEL Reports Second Quarter 2026 Financial Results

August 17, 2026

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

June 3, 2026

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

May 18, 2026

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

May 13, 2026

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

May 12, 2026

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

May 5, 2026

NEXGEL Appoints Ian Blackman as Chief Financial Officer

April 27, 2026

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

April 21, 2026

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4: 30 P.M. ET

April 17, 2026

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4: 30 P.M. ET to Provide Update on Celularity Transaction

April 15, 2026

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4: 30 P.M. ET to Provide Update on Celularity Transaction

April 7, 2026

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4: 30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

March 30, 2026

NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

March 25, 2026

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

March 11, 2026

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

March 9, 2026

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

February 10, 2026

Calls in 2026

Decks in 2026